|
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial. |
|
|
Honoraria - Abbvie; Celgene; Jazz Pharmaceuticals; Novartis |
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Astex Pharmaceuticals; Celgene; Jazz Pharmaceuticals; Roche |
Research Funding - Amgen (Inst); Arog (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst) |
|
|
Honoraria - Abbvie/Genentech; Amgen; Celgene; Janssen Oncology; Novartis; Pfizer; Roche; SERVIER |
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Celgene; Macrogenics; Novartis; Pfizer; SERVIER |
Speakers' Bureau - Abbvie/Genentech; Amgen; Celgene; Novartis |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Novartis (Inst); Servier (Inst) |
Patents, Royalties, Other Intellectual Property - AW is a former employee of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to venetoclax, and is eligible for benefits related to these payments. AW receives payments from WEHI related to venetoclax |
Travel, Accommodations, Expenses - Abbvie; Amgen; Celgene; Janssen Oncology; Novartis; Pfizer; Servier |
|
|
Consulting or Advisory Role - Abbvie; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer; Roche; Shire |
Speakers' Bureau - Celgene; Daiichi Sankyo; Otsuka |
Research Funding - Celgene (Inst); Janssen-Cilag (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Orsenix; Pfizer; Seagen; Sunesis Pharmaceuticals |
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Jazz Pharmaceuticals; Orsenix; Seagen; Sunesis Pharmaceuticals |
Research Funding - Amgen; Bristol-Myers Squibb; Cellerant; Macrogenics; Merck; Seagen; Selvita; Sunesis Pharmaceuticals; Xencor |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis |
Speakers' Bureau - Abbvie; Amgen; Jazz Pharmaceuticals; Novartis |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Abbvie; Amgen; Daiichi Sankyo; Janssen; Jazz Pharmaceuticals; Novartis |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
|
|
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Jazz Pharmaceuticals |
Travel, Accommodations, Expenses - Agios; Amgen; Bristol-Myers Squibb; Jazz Pharmaceuticals |
|
|
Consulting or Advisory Role - Agen; Agios; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Johnson & Johnson; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Johnson & Johnson (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; Amphivena; argenx; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; Bayer; Bayer; Celgene; Celltrion; Daiichi Sankyo; Eisai; Genentech/Roche; Genoptix; Janssen; Jazz Pharmaceuticals; MedImmune; MEI Pharma; Novartis; Orsenix; Otsuka; Pfizer; Roche; Sandoz; Takeda; Trovagene |
Research Funding - Abbvie (Inst); Agios (Inst); amphivena (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); Cellectis (Inst); CTI (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst) |
Travel, Accommodations, Expenses - Abbvie; Agios; Amgen; Amphivena; Array BioPharma; Astex Pharmaceuticals; Bayer; Celgene; Celltrion; Clovis Oncology; Eisai; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Roche/Genentech; Sandoz; Sunesis Pharmaceuticals |